Singapore, Sept. 13 -- Teijin Limited, Teijin Regenet Co., Ltd., and Shinshu University Hospital have entered into a joint research agreement regarding manufacturing technologies for cell and gene therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. The collaboration aims to advance manufacturing technologies and strengthen Japan's manufacturing infrastructure for cell and gene therapies, thereby contributing to the broader availability of these innovative treatments.

Published by HT Digital Content Services with permission from BioSpectrum Asia....